AGIO

Agios Pharmaceuticals, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-02-12

Figures on this page computed 2026-11-08 13:19 UTC

Last close

28.27USD

Market data, 2026-11-05

AGIO: weekly closes from 33.56 on 2026-08-14 to 28.27 on 2026-11-05, a move of -15.8%. Prices in USD.

Weekly closes, 2026-08-14 to 2026-11-05

Over that span: -15.8%

Except where said otherwise: 10-K for 2025, filed 2026-02-12

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001439222-26-000025
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-12
The filing itself
-41.2%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001439222-26-000025
Reported in
USD
- 10-K for 2025, filed 2026-02-12
- 10-K for 2025, filed 2026-02-12
- 10-K for 2025, filed 2026-02-12
- 10-Q for 2025, filed 2026-07-30
- 10-K for 2025, filed 2026-02-12
- 10-Q for 2025, filed 2026-07-30
The filing itself
-764.0%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001439222-26-000025
Reported in
USD
- 10-K for 2025, filed 2026-02-12
- 10-K for 2025, filed 2026-02-12
The filing itself
-698.3%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001439222-26-000025
Reported in
USD
- 10-K for 2025, filed 2026-02-12
- 10-K for 2025, filed 2026-02-12
The filing itself
0.03Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001439222-26-000025
Reported in
USD
- 10-K for 2025, filed 2026-02-12
- 10-Q for 2025, filed 2026-07-30
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Growth is the furthest below its sector's middle: 0.12 against 0.46 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

1.18x

13.05x

1.24x

0.52x

0.65x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-05

Each against its own average

5 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-02-12

Sales1.18x
Its own average over 10 years, 45.7M.
Profit13.05x
Its own average over 10 years, -31.6M.
Free cash flow1.24x
Its own average over 10 years, -305.3M.
Debt0.52x
Its own average over 6 years, 77.6M.
Price0.65x
Its own average over 11 years, 43. Market data, 2026-11-05

Profit is furthest from its own average, at 13.05 times.

The filed years, as a table

Each line is 100 at 2016-12-31, the first year we hold.

Filed year	Sales	Shares in issue
2016-12-31	100.0	n/a
2017-12-31	61.5	n/a
2018-12-31	135.0	n/a
2019-12-31	168.7	100.0
2020-12-31	0.0	115.0
2021-12-31	0.0	100.8
2022-12-31	20.4	91.3
2023-12-31	38.4	92.8
2024-12-31	52.2	96.5
2025-12-31	77.3	96.6

How sales was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0001439222-26-000025
Reported in: USD

The filing itself

How shares in issue was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0001439222-26-000025
Reported in: USD

The filing itself

Figures behind the shape

Growth

-161.3%

faster is higher, placed against 4,950 companies as of 2026-11-07

Five-year revenue growth raten/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
Five-year EPS growth raten/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
One-year change in net income-161.3%
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Returns on capital

-41.2%

higher is higher, placed against 5,089 companies as of 2026-11-07

Return on invested capital-41.2%
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001439222-26-000025
Reported in
USD
- 10-K for 2025, filed 2026-02-12
- 10-K for 2025, filed 2026-02-12
- 10-K for 2025, filed 2026-02-12
- 10-Q for 2025, filed 2026-07-30
- 10-K for 2025, filed 2026-02-12
- 10-Q for 2025, filed 2026-07-30
The filing itself
Return on equity-34.6%
Net Income / Shareholders' Equity x 100
Source
computed
Fiscal year
2025
Accession
0001439222-26-000025
Reported in
USD
- 10-K for 2025, filed 2026-02-12
- 10-Q for 2025, filed 2026-07-30
The filing itself
Return on assets-31.8%
Net Income / Total Assets x 100
Source
computed
Fiscal year
2025
Accession
0001439222-26-000025
Reported in
USD
- 10-K for 2025, filed 2026-02-12
- 10-Q for 2025, filed 2026-07-30
The filing itself

Margins

88.3%

wider is higher, placed against 3,412 companies as of 2026-11-07

Gross margin88.3%
Gross Profit / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001439222-26-000025
Reported in
USD
- 10-K for 2025, filed 2026-02-12
- 10-K for 2025, filed 2026-02-12
The filing itself
Operating margin-873.9%
Operating Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001439222-26-000025
Reported in
USD
- 10-K for 2025, filed 2026-02-12
- 10-K for 2025, filed 2026-02-12
The filing itself
Net margin-764.0%
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001439222-26-000025
Reported in
USD
- 10-K for 2025, filed 2026-02-12
- 10-K for 2025, filed 2026-02-12
The filing itself
Free cash flow margin-698.3%
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001439222-26-000025
Reported in
USD
- 10-K for 2025, filed 2026-02-12
- 10-K for 2025, filed 2026-02-12
The filing itself

Price

1.4x

cheaper is higher, placed against 4,362 companies as of 2026-11-07

Price to earningsn/a
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001439222-26-000025
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-12
The filing itself
Price to book1.4x10-Q for 2025, filed 2026-07-30
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
Source
computed
Fiscal year
2025
Accession
0001439222-26-000118
Reported in
USD
- computed
- 10-Q for 2025, filed 2026-07-30
- computed
- 10-K for 2025, filed 2026-02-12
The filing itself
EV to EBITDAn/a
We do not hold this figure for this company, so there is nothing to place.
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001439222-26-000025
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-12
- 10-K for 2025, filed 2026-02-12
- 10-Q for 2025, filed 2026-07-30
- 10-K for 2025, filed 2026-02-12
The filing itself
Price to sales ratio31.6x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
Source
computed
Fiscal year
2025
Accession
0001439222-26-000025
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-12
- 10-K for 2025, filed 2026-02-12
The filing itself

Safety

0.03

safer is higher, placed against 3,227 companies as of 2026-11-07

Debt to equity0.03
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001439222-26-000025
Reported in
USD
- 10-K for 2025, filed 2026-02-12
- 10-Q for 2025, filed 2026-07-30
The filing itself
Current ratio11.4610-Q for 2025, filed 2026-07-30
Current Assets / Current Liabilities
Source
computed
Fiscal year
2025
Accession
0001439222-26-000118
Reported in
USD
- 10-Q for 2025, filed 2026-07-30
- 10-Q for 2025, filed 2026-07-30
The filing itself
Interest coveragen/a
We do not hold this figure for this company, so there is nothing to place.
Operating Income / Interest Expense
Source
computed
Fiscal year
2025
Accession
0001439222-26-000025
Reported in
USD
- 10-K for 2025, filed 2026-02-12
- 10-K for 2025, filed 2026-02-12
The filing itself
Altman Z-Score8.86
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
Source
computed
Taken on
2026-11-07
Reported in
USD
- Computed from the 10-K for 2025, filed 2026-02-12
- Computed from the 10-K for 2025, filed 2026-02-12
- Computed from the 10-K for 2025, filed 2026-02-12
- Computed from the 10-K for 2025, filed 2026-02-12
- Computed from the 10-K for 2025, filed 2026-02-12

What it pays out

n/a

We do not hold this figure for this company, so there is nothing to place.

more, and better covered, is higher, with no cohort held

Dividend yieldn/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
Payout ration/a
We do not hold this figure for this company, so there is nothing to place.
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
Source
computed
Fiscal year
2025
Accession
0001439222-26-000025
Reported in
USD
- 10-K for 2025, filed 2026-02-12
- Computed from the 10-K for 2025, filed 2026-02-12
- 10-K for 2025, filed 2026-02-12
The filing itself
Dividend cover ration/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Share a finding

A link to the finding, not to you: it carries nothing about your account.